2025 Nobel Prize: A Milestone for Autoimmunity Research – Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
Jan Hartmann, Chief Medical Officer at Haemonetics, shared on LinkedIn:
‘‘2025 Nobel Prize: A Milestone for Autoimmunity Research
This year’s Nobel Prize in Physiology or Medicine was awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their groundbreaking discoveries in peripheral immune tolerance, specifically the identification and function of regulatory T cells (Tregs) and the pivotal role of the FOXP3 gene.
Their work has transformed our understanding of how the immune system distinguishes between self and non-self—and how it prevents destructive autoimmune responses.
These insights offer a deeper understanding of autoimmune diseases, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Myasthenia Gravis (MG).
In both conditions, the immune system mistakenly attacks components of the nervous system, leading to debilitating symptoms.
Research suggests that patients with CIDP and MG may exhibit deficient or dysfunctional Tregs, and reduced FOXP3 expression, contributing to the breakdown of immune tolerance.
Immunoglobulin Therapies: A Cornerstone of Care
While the Nobel laureates’ discoveries are foundational, they also reinforce the importance of existing therapies.
For example, intravenous and subcutaneous immunoglobulin (IVIG/SCIG) have long been a mainstay in the treatment of CIDP and MG.
These plasma-derived medicines help modulate immune responses and mitigate the consequences of unregulated autoimmunity.
The convergence of Nobel-level science and clinical practice underscores a powerful message: a deeper understanding of immune regulation is key to advancing therapies—both established and emerging.”
Read more on Nobel Prize in Physiology or Medicine 2025.
Stay updated on the important with Hemostasis Today.
-
Aug 29, 2026, 14:07Vincent Rizzo: Beta Blocker Choice May Impact Portal Vein Thrombosis and Survival in Cirrhosis
-
Aug 29, 2026, 14:04Günalp Uzun: DGTI 2026 New Insights in Platelet Immunology and Hemostasis
-
Aug 29, 2026, 13:59Eleftheria Hatzimichael: ASH 2026 Guidelines for Primary ITP What Is Changing
-
Aug 29, 2026, 11:03Richard Davis: Navigating Acute PE – ESC vs. the New AHA/ACC Guidelines
-
Aug 29, 2026, 10:57Bartosz Hudzik: First RCT Evidence for a Long-Standing Guideline Gray Zone
-
Aug 29, 2026, 10:50Edward Lee Carter: Breakthrough Stroke Beyond ‘DOAC Failure’ – Risk Stratification Insights from ASPERA-R
-
Aug 29, 2026, 10:45Amir Askarinejad: SINGLE-AF at ESC 2026 – Important New Data for Anticoagulation in Intermediate-Risk AF
-
Aug 29, 2026, 10:26Paulus Kirchhof: Anticoagulation in Patients with a Single CHADS-VA Risk Factor
-
Aug 29, 2026, 10:22Syed Zohad Shah: Reducing Blood Loss and Hospital Stays in Non-Cardiac Thoracic Surgery